Shanghai Kehua Bio-Engineering Co Ltd
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated co… Read more
Shanghai Kehua Bio-Engineering Co Ltd (002022) - Total Assets
Latest total assets as of September 2025: CN¥5.17 Billion CNY
Based on the latest financial reports, Shanghai Kehua Bio-Engineering Co Ltd (002022) holds total assets worth CN¥5.17 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Kehua Bio-Engineering Co Ltd - Total Assets Trend (2001–2024)
This chart illustrates how Shanghai Kehua Bio-Engineering Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai Kehua Bio-Engineering Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Kehua Bio-Engineering Co Ltd's total assets of CN¥5.17 Billion consist of 54.2% current assets and 45.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.5% |
| Accounts Receivable | CN¥899.56 Million | 17.2% |
| Inventory | CN¥875.20 Million | 16.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥533.97 Million | 10.2% |
| Goodwill | CN¥660.30 Million | 12.6% |
Asset Composition Trend (2001–2024)
This chart illustrates how Shanghai Kehua Bio-Engineering Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Kehua Bio-Engineering Co Ltd's current assets represent 54.2% of total assets in 2024, a decrease from 68.6% in 2001.
- Cash Position: Cash and equivalents constituted 16.5% of total assets in 2024, down from 22.1% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 17.2% of total assets.
Shanghai Kehua Bio-Engineering Co Ltd Competitors by Total Assets
Key competitors of Shanghai Kehua Bio-Engineering Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
JVM Co. Ltd
KQ:054950
|
Korea | ₩296.91 Billion |
Shanghai Kehua Bio-Engineering Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shanghai Kehua Bio-Engineering Co Ltd generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shanghai Kehua Bio-Engineering Co Ltd is currently not profitable relative to its asset base.
Shanghai Kehua Bio-Engineering Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 4.55 | 3.18 |
| Quick Ratio | 1.53 | 3.17 | 2.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.49 Billion | CN¥ 2.69 Billion | CN¥ 2.75 Billion |
Shanghai Kehua Bio-Engineering Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Kehua Bio-Engineering Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -23.1% |
| Total Assets | CN¥5.24 Billion |
| Market Capitalization | $318.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Kehua Bio-Engineering Co Ltd's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Kehua Bio-Engineering Co Ltd's assets decreased by 23.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Kehua Bio-Engineering Co Ltd (2001–2024)
The table below shows the annual total assets of Shanghai Kehua Bio-Engineering Co Ltd from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.24 Billion | -23.09% |
| 2023-12-31 | CN¥6.81 Billion | -22.75% |
| 2022-12-31 | CN¥8.81 Billion | +26.71% |
| 2021-12-31 | CN¥6.96 Billion | +16.36% |
| 2020-12-31 | CN¥5.98 Billion | +61.33% |
| 2019-12-31 | CN¥3.70 Billion | +5.74% |
| 2018-12-31 | CN¥3.50 Billion | +29.02% |
| 2017-12-31 | CN¥2.72 Billion | +16.89% |
| 2016-12-31 | CN¥2.32 Billion | +12.15% |
| 2015-12-31 | CN¥2.07 Billion | +44.96% |
| 2014-12-31 | CN¥1.43 Billion | +4.30% |
| 2013-12-31 | CN¥1.37 Billion | +6.59% |
| 2012-12-31 | CN¥1.29 Billion | +6.97% |
| 2011-12-31 | CN¥1.20 Billion | +10.57% |
| 2010-12-31 | CN¥1.09 Billion | +17.40% |
| 2009-12-31 | CN¥925.84 Million | +25.57% |
| 2008-12-31 | CN¥737.31 Million | +20.35% |
| 2007-12-31 | CN¥612.64 Million | +26.45% |
| 2006-12-31 | CN¥484.49 Million | +6.01% |
| 2005-12-31 | CN¥457.03 Million | +2.63% |
| 2004-12-31 | CN¥445.33 Million | +84.61% |
| 2003-12-31 | CN¥241.23 Million | +6.98% |
| 2002-12-31 | CN¥225.50 Million | +35.18% |
| 2001-12-31 | CN¥166.81 Million | -- |